Travere Therapeutics, Inc. Common Stock
Here’s whether Travere Therapeutics, Inc. Common Stock (TVTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+7.62% over 10 days); strong 1-year return of +112.5%; 3-month momentum positive (+33.3%). Concerns: RSI 77 — overbought, elevated pullback risk; declining volume on rally — weak conviction (0.75x 30d avg). Currently 1.3% off its 52-week high. Score: +4/7.
TVTX is in a confirmed uptrend, trading above both its 50-day ($32.30) and 200-day ($28.77) moving averages. With an RSI of 77.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +112.5% compares to +27.9% for SPY (beat the market by 84.6%).